Cambridge Healthtech Institute’s Inaugural

Targeting Innate Immunity Congress

Harnessing Natural Killer, Macrophage and Dendritic Cells for New Cancer Immunotherapies

December 5-6, 2017 | Hilton San Diego Resort | San Diego, CA

While a large portion of cancer immunotherapies focus on targeting T cells, there has been a surge of interest in harnessing the relatively underexplored innate immune system for therapeutic intervention, with particular focus on natural killer (NK) cells, macrophages and dendritic cells. A growing number of studies into pathways elucidating innate cell biology, and the development of therapeutic agents to activate or suppress cell function, have set the stage for a new generation of cancer immunotherapies.

Cambridge Healthtech Institute’s Inaugural Targeting Innate Immune Cells conference will convene immuno-oncology researchers, cancer immunotherapy developers, and technology providers to discuss current challenges and opportunities, from discovery immuno-oncology to clinical studies, share latest technologies and development approaches, as well as to provide updates on preclinical, clinical, and combination studies.